

November 12, 2019

То	To
Listing Department,	The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED	BSE LIMITED
Exchange Plaza,	Phiroz Jeejeebhoy Towers,
Bandra Kurla Complex, Bandra (E),	25th floor, Dalal Street,
MUMBAI -400 051	MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir,

#### Sub: Outcome of Board Meeting held on November 12, 2019.

The Board of Directors of the Company at its meeting held today, November 12, 2019, has inter alia, transacted the following businesses:

- Approved the Un-audited Financial Results of the Company for the second Quarter and half year ended September 30, 2019 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.
- Approved an Interim Dividend @ 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2019-20. The Company has fixed November 23, 2019 as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before December 4, 2019.

We enclose a copy of the Press Release on Un-audited Financial Results of the Company for the second quarter and half year ended September 30, 2019.

The Board meeting commenced at 2.00 p.m and concluded at 5:45 p.m.

Yours faithfully, For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

Enclosures: as above.

(CIN: L24239TG1986PLC015190)



# AUROBINDO PHARMA LIMITED

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No. 11, Survey No.9, Ili-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059 Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com W W W . a urobindo.com

#### AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF UNAUDITED STANDALONE F						Versended
		Quarter ended		Half year		Year ended
Particulars	30.09.2019 Unaudited	30.06.2019 Unaudited	30.09.2018 Unaudited	30.09.2019 Unaudited	30.09.2018 Unaudited	31.03.2019 Audited
	Gilduited	Unaddited	Unduried	Ghilloneu	Unduriced	Addited
1 Revenue from operations		1000	P			the states
(a) Net sales/ income from operations	314,512	299,703	309,038	614,215	558,200	1,193,87
(b) Other operating income	7,654	8,180	8,001	15,834	14,721	31,91
Total revenue from operations	322,166	307,883	317,039	630,049	572,921	1,225,78
2 Other income			· · · · · · · · · · · · · · · · · · ·		C. C. Lawrence	
(a) Foreign exchange gain (net)		2,474		2,038	S 191	191
(b) Others	3,364	540	418	3,904	700	10,96
Total other income	3,364	3,014	418	5,942	700	10,96
Total income (1+2)	325,530	310,897	317,457	635,991	573,621	1,236,74
3 Expenses				1000		
(a) Cost of materials consumed	158,616	161,540	160,899	320,156	304,296	645,53
(b) Purchase of stock-in-trade	134	238	743	372	996	1,42
(c) Changes in inventories of finished goods, stock-in-trade and	3,801	(7,572)	(1,134)	(3,771)	(13,047)	(28,980
work-in-progress	20.000	00.000	22.400	75.463	CT 400	
(d) Employee benefits expense	37,406	37,756	33,180	75,162	65,109	136,27
(e) Finance costs	Z,486	3,195	3,080	5,681	5,467	13,09
(f) Foreign exchange loss (net)	436		2,294		7,290	1,03
(g) Depreciation and amortisation expense	11,793	11,515	10,094	23,308	19,460	41,30
(h) Other expenses	58,652	60,880	60,360	119,532	107,904	230,60
Total expenses	273,324	267,552	269,516	540,440	497,475	1,040,28
Profit before tax (1+2-3)	52,206	43,345	47,941	95,551	76,146	196,46
5 Tax expense					11 - CAS (	
Current tax	10,865	9,361	10,456	19,082	16,619	42,66
Tax credit - Miminum Alternate Tax (MAT)	1.00	(1,144)	(3,195)		(3,864)	(4,80
Deferred tax	1,528	2,078	2,585	3,606	2,784	5,63
Total tax expense	12,393	10,295	9,846	22,688	15,539	43,48
6 Profit for the period/year (4-5)	39,813	33,050	38,095	72,863	60,607	152,97
Other Comprehensive income			1		and the later	1.
Items that will not to be reclassified subsequently to profit or loss:		1.1	1		10100	
(a) Re-measurement of defined benefit liability	(680)	(55)	(2)	(735)	(98)	(21)
(b) Income-tax relating to items that will not be reclassified to profit	238	19	1	257	34	7
or loss	250	13			24	
Total Comprehensive income for the period/year (6+7)	39,371	33,014	38,094	72,385	60,543	152,83
Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859	5,85
Other equity	3,033	2,023	2001	2,005	5,000	1,129,20
Earnings per equity share (face value Re. 1 per share)	not annualised	not annualised	not annualised	not annualised)	not annualised	and the second sec
(a) Basic (in Rs.)	6.80	5.64	6.50	12.44	10.34	26.1
(b) Diluted (in Rs.)	6.80	5.64	6.50	12.44	10.34	26.1



FOR IDENTIFICATION ONLY

DO PA

HYD

ROB

- NOTES:
  - 1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
  - 2 The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 November 2019. The statutory auditors have carried out limited review of the above results for the quarter and half year ended 30 September 2019. An unqualified report has been issued by them thereon.
  - 3 Effective 1 April 2019, the Company adopted Ind-AS 116, on all lease contracts existing on 1 April 2019 using the modified retrospective method with Right-of-use assets recognized at an amount equal to the lease liabilities in the balance sheet. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. On transition, the adoption of the standard resulted in recognition of Right-of-use assets (ROU) of Rs. 3,787 lakhs (includes reclassification of finance lease assets of Rs. 1,368 lakhs as at 31 March 2019) and lease liabilities of Rs. 2,419 lakhs. The Right-of-use assets as on 30 September 2019 have been presented as part of Property, plant and equipment.
  - 4 The Company operates in only one segment viz,, 'Pharmaceutical Products'.
  - 5 Sales of standalone include exports of Rs.266,617 lakhs for the current quarter (30 September 2018: Rs.261,136 lakhs).
  - 6 The Company has alloted 23,000 equity shares of Re.1/- (Rupee One only) on 7 August, 2019 to the employees under Employee Stock option plan 2006. Consequent to the allotment, the paid-up share capital of Company has increased from 58,59,15,609 to 58,59,38,609 equity shares of Re.1/- each. These options were fully vested during the year ended 31 March 2017.
  - 7 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendement) Ordinance 2019, inserted a new Section 115BAB in the Income tax Act, 1961, which provides an option to the Company for paying income Tax at reduced rates as per the provisions/conditions defined in the said section. The Company is in the process of evaluting its position with respect to the aforesaid option.
  - 8 The Board in its meeting held on 28 May 2019 approved the Scheme of Amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited with the Company. The Company has filed an Application C.A. (CAA) NO. 201/230/HDB/2019 before the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT) on 7 August 2019. The NCLT had passed an Order on 30 September 2019 and directed to convene the meetings of Equity Shareholders and Un-secured Creditors of the Company and the subsidiaries covered under merger scheme, on 30 November 2019. Pending the disposal of the application by NCLT, no adjustment has been made to the results for the period/year reported.
- 9 SEBI (Securities and Exchange Board of India) vide notification dated 9 May 2018 mandated submission of the statement of cash flows by way of a note as part of the half yearly financial results w.e.f 1 April 2019. Since this is the first period/year of requirement for submission of the statement of cash flows and as there is no specific gudiance by SEBI, the comparative information has been provided for the previous year ending 31 March 2019.
- 10 The Board has approved interim dividend @125% i.e.Re.1.25 (Rupee One and Twenty five palse only) per equity share of Re.1 (Rupee One only) for the year 2019-20.
- 11 Previous period figures have been regrouped/ rearranged wherever considered material and necessary to conform to the current period presentation.

OPHA WINNIN

By Order of the Board



Place: Hyderabad

Date :12 November 2019

FOR IDENTIFICATION ONLY

SI.	DADTICIUADC	Asat	As at
1004	PARTICULARS	As at 30.09.2019	As at 31.03.2019
No.		(Unaudited)	(Audited)
		(onsurred)	(Huditeu)
1.1	ASSETS		
1	Non-current assets	1.1.1.1.1.1.1	
	Property, plant and equipment	428,644	414,585
	Capital work-in-progress	74,044	75,00
	Intangible assets	337	385
1.1	Intangible assets under development	100	3,894
	Financial assets	1.000	
	Investments	247,571	233,904
	Loans	24,690	14,656
	Trade receivables	10 705	0.033
	Other financial assets	10,205	9,827
	Non-current tax assets (net) Other non-current assets	17,391 5,063	13,811
	Total non-current assets	807,945	773,238
2	Current assets		
	Inventories	429,639	397,126
19	Financial assets	120,000	357,1220
	Investments	2	
	Trade receivables	480,969	523,207
	Cash and cash equivalents	22,973	7,340
	Bank balances other than cash and cash equivalents	237	237
	Loans	1,063	982
	Other financial assets	2,173	2,025
	Other current assets	102,834	109,915
1	Total current assets	1,039,890	1,040,834
	TOTAL ASSETS	1,847,835	1,814,072
	EQUITY AND LIABILITIES		
	Equity		
	Equity share capital	5,859	5,859
	Other equity	1,201,605	1,129,203
	Total equity	1,207,464	1,135,062
	Liabilities		
2	Non-current liabilities		
	Financial liabilities		
	Lease liabilities	1,114	
	Provisions	2,954	2,264
	Deferred tax liability (net)	9,350	3,100
	Total non-current liabilities	13,418	5,364
3	Current llabilities		
	Financial liabilities	1. (D. 1.)	
	Borrowings	372,753	451,980
	Lease liabilities	959	2
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises and	5,650	3,288
	total outstanding dues of creditors other than micro enterprises and small enterprises	170,377	180,851
	Other financial liabilities	47,344	12,869
	Other current liabilities	19,164	15,007
	Provisions Total current liabilities	10,706 626,953	9,651 673,646
	Lotal current liabilities	676 953	673 646



FOR IDENTIFICATION ONLY



I. PAR	TICULARS	For the half year ended	For the year ended	
100		30.09.2019	31.03.2019	
1		(Unaudited)	(Audited)	
1 CASH	I FLOW FROM OPERATING ACTIVITIES		-	
Net p	profit before tax	95,551	196,462	
Adjus	stments to reconcile profit before tax to net cash flow:		Constant and	
	preciation and amoritsation expense	23,308	41,302	
	owances for doubtful receivables/ provision for advances and other assets (net)	(2,316)	1,623	
	d debts	105	20	
	ovisions no longer required written back			
	2 일 전 가 은 가 등 기 등 가 <b>원</b> , 가 이 가 있는 것 같은 것 같은 것 같은 것 같은 것 같은 것 같이 있는 것 같이 있는 것 같이 있는 것 같은 것 같	(11)	(999	
	irealised foreign exchange gain (net)	(438)	(53)	
	ark-to-market gain on derivative financial instruments	(601)	(64)	
	ss on sale of property, plant and equipment (net)	49	1,06.	
1.0000	end income		(7,90)	
Finan	ice costs	5,474	12,66	
Intere	est income	(1,080)	(683	
1.1		all and the second		
Opera	ating profit before working capital changes	120,041	242,362	
	ements in working capital:		- to the second	
	ease/(increase) in trade receivables	50,907	(87,81)	
	ase in inventories	(32,513)	(56,20	
10.000	ase in loans			
10000		(65)	(17,	
	ease/(increase) in other financial assets	528	(29	
	ease/(increase) in other current/non-current assets	7,645	(20,82	
and the second second	ase in trade payables	24,030	22,86	
	ase in provision for retirement benefits	1,009	88	
Increa	ase/(decrease) in other financial liabilities		(21	
Increa	ase in other current liabilities	4,157	61	
Cash	generated from operating activities	175,739	101,20	
Incon	ne-tax paid (net)	(19,760)	(48,21)	
	ash flow generated from operating activities (A)	155,979	52,98	
1000				
2 CASH	FLOW FROM INVESTING ACTIVITIES			
The second		122 0(0)	100.000	
	hase of property, plant and equipment including movement in	(32,869)	(89,006	
capita	al work-in-progress, capital advances and capital creditors	1.		
Sale c	of intangible assets under development	3,894	1.1.1.1	
	eds from sale of property, plant and equipment	300	30	
100 C	lase of non-current investments	(13,092)	(35,81	
1 2 2 2 2 2 2 2 2	end received from subsidiary	(13,052)	7,90	
	s made to subsidiaries	(14 400)		
		(14,400)	(13,31	
	s repaid by subsidiaries	4,350		
	est received	691	18	
Net c	ash flow used in investing activities (B)	(51,126)	(129,73	
3 CASH	FLOW FROM FINANCING ACTIVITIES			
Proce	eds from issuance of equity share capital	19		
Repay	yment of non-current borrowings		(6,51	
(Repa	syment of) / proceeds from current borrowings (net)	(82,986)	95,17	
	yment of lease liabilities, net	(434)		
	est paid	(5,412)	(12,73	
	ends paid on equity shares	(2)122/	(14,60	
	aid on equity dividend	131	(1,38	
	ash flow (used in)/generated from financing activities (C)	100.0171		
Net G	ash now (used in)/generated from mancing activities (c)	(88,813)	59,94	
1000	and the second second second second second	1.000	1000	
	ncrease/(decrease) in cash and cash equivalents (A+B+C)	16,040	(16,80	
1	and cash equivalents at the beginning of the period/year	6,870	23,99	
	t of exchange differences on cash and cash equivalents	52	(31	
Cash	and cash equivalents at the end of the period/year	22,962	6,87	
1100				
Cash	and cash equivalents comprises of:			
	on hand	10		
100000		12	1	
1.000	ues on hand	1.54	2,82	
1.000	ce with banks:	0.24	1.44	
	rrent accounts	9,484	4,03	
	sh credit accounts (net)	13,466	-	
Cash	and Cash equivalents considered for cash flows	22,962	6,87	
	Care Court Mark Andre Street and Court Mark and Care Andre Street			

The above statement of cash flows has been prepared under the "Indirect method" as set out in Ind AS 7, "Statement of cash flows",

es pssociates 8.00 E TED ACCU FOR IDENTIFICATION ONLY

. U.A.R

N NDO PH 2 ROB HYD Page 4 of 4

# **BSR&Associates LLP**

#### **Chartered Accountants**

Salarpuria Knowledge City Orwell, B Wing, 6th Floor, Unit-3 Sy. No. 83/1, Plot No. 2, Raidurg Hyderabad-500081, India. Telephone +91 40 7182 2000 Fax +91 40 7182 2399

Independent Auditor's Review Report on Unaudited Quarterly and Year to date Standalone Financial Results of Aurobindo Pharma Limited under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

To

Board of Directors of Aurobindo Pharma Limited

- We have reviewed the accompanying statement of unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") for the quarter ended 30 September 2019 and year to date results for the period from 1 April 2019 to 30 September 2019 ("the Statement").
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP** Chartered Accountants Firm Registration Number: 116231W/W-100024

Sriram Mahalingam Partner Membership Number: 049642 UDIN: 19049642 AAAEA3075

Place: Hyderabad Date: 12 November 2019

> B S R & Associates (a partnership firm with Registration No BA69226) converted into B S R & Associates LLP (a Limited Lability Partnership with LLP Registration No AAB-B182) with effect from October 14, 2013

Registered Office: 5th Floor, Lodha Excelus Apollo Mills Compound N M Joshi Marg, Mahalakshm Mumbai - 400 011

#### AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190) Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

0

STATEMENT OF UNAUDITED CONSOLIDATED FIN	ANCIAL RESULTS F	OR THE QUART	ER AND HALF YE	AR ENDED 30.09	.2019	
		Quarter ended		Half year		Year ender
Particulars	30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
1 4 42	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
				1.1.1.1.1.1		
1 Revenue from operations		- Greek	1000	100000	The Designation	Cornel 1
(a) Net sales/ income from operations	551,827	535,684	466,712	1,087,511	884,868	1,922,59
(b) Other operating income	8,220	8,776	8,428	16,996	15,299	33,76
Total revenue from operations	560,047	544,460	475,140	1,104,507	900,167	1,956,35
2 Other income	1 A A A A A A A A A A A A A A A A A A A	i i i i i i i i i i i i i i i i i i i		Contraction of the	100 - 100	
(a) Foreign exchange gain (net)		478	1.			
(b) Others	2,062	1,100	2,626	3,162	6,999	11,5
Total other income	2,062	1,578	2,626	3,162	6,999	11,5
Total income (1+2)	562,109	546,038	477,766	1,107,669	907,166	1,967,9
3 Expenses	1.1		1.0	1.000	1000	1.00
(a) Cost of materials consumed	181,547	186,038	187,436	367,585	353,114	744,4
(b) Purchase of stock-in-trade	51,570	53,007	44,402	104,577	87,915	194,3
(c) Changes in inventories of finished goods, stock-in-trade and work-in-		(9,191)	(27,549)	(5,476)	(46,015)	(67,55
progress	77 710	77.096	63 540	100 700	122.101	-
(d) Employee benefits expense	77,719	77,986	62,548	155,705	122,161	258,4
(e) Finance costs	4,094	4,989	3,539	9,083	6,493	16,2
(f) Foreign exchange loss (net)	2,723	24.000	3,973	2,245	10,789	6,0
(g) Depreciation and amortisation expense	24,331	24,086	16,368	48,417	31,821	66,7
(h) Other expenses	128,751	121,980	105,703	250,731	202,470	431,4 1,650,2
Total expenses	474,450	458,895	396,420	932,867	768,748	1,050,2
4 Profit before share of profit of joint ventures, exceptional items and tax	87,659	87,143	81,346	174,802	138,418	317,6
(1+2-3)		171		470		
5 Share of profit of joint ventures, net of tax	07.000	471	24	478	65	2
6 Profit before exceptional items and tax (4+5)	87,666	87,614	81,370	175,280	138,483	317,9
7 Exceptional items (refer note 5)	1,276	1,270	2,684	2,546	2,684	8,8
8 Profit before tax (6-7) 9 Tax expense	86,390	86,344	78,686	172,734	135,799	309,1
	21 605	20.660	10 907	41 220	30,845	74.7
Current tax Tax credit - Miminum Alternate Tax (MAT)	21,695 (237)	20,669 (1,144)	19,897 (3,539)	41,220 (237)	(4,207)	71,2
Deferred tax	979	3,251	1,184	4,230	2,458	6,5
Total tax expense	22,437	22,776	17,542	45,213	29,096	72,6
0 Profit for the period/year (8-9)	63,953	63,568	61,144	127,521	106,703	236,4
1 Other Comprehensive Income	44,534	03,500	01,144	127,522	100,703	230,4
A) Items that will not be reclassified subsequently to profit or loss:						
i) Re-measurement of defined employee benefit liability	(686)	(55)	8	(741)	(89)	(2
ii) Income-tax relating to items that will not be reclasified to profit or	239	19	1	258	35	1
loss						
B) Items that will be reclassified subsequently to profit or loss:				1	22.12	
i) Exchange differences on translating the financial statements of	2,154	1,044	19,154	3,198	22,680	(20
foreign operations			1.1.1	1.1	1.1	
<ul> <li>ii) Income-tax on items that will be reclassified subsequently to profit or loss</li> </ul>	- A		1	8		
	126	1.1.2.2		1000	2252	
Total other comprehensive income for the period/year (net of tax)	1,707	1,008	19,163	2,715	22,626	(42
Z Total Comprehensive income for the period/year (net of tax) (10+11)	65,660	64,576	80,307	130,236	129,329	236,0
Attributable to:		11.000	and and	here	Vennee	
Owners of the Parent Company	65,693	64,591	80,306	130,284	129,335	236,0
Non-controlling interest	(33)	(15)	1	(48)	(6)	(
Out of total comprehensive income above,				1.00		
Profit for the year attributable to:	1 1 2 2 4 1	11 10 10 10	10.5	1000	1.1	1
Owners of the Parent Company	63,986	63,583	61,151	127,569	106,709	236,4
Non-controlling interest	(33)	(15)	(7)	(48)	(6)	(3
Other comprehensive income attributable to:	1.	100	1.0		and second to	
Owners of the Parent Company	1,707	1,008	19,163	2,715	22,626	(4:
Non-controlling interest		121			1.1.1.1.1.1.1	4
	E (000	5,859	5,859	5,859	5,859	5,8
3 Paid-up equity share capital (face value Re. 1 per share) 4 Other equity	5,859	5,859	5,659	669,6	2,629	1,383,2
	(not annualised) (	not annualizad	(not annualized	not annualized	not annualized	1,383,2 (annualise
5 Earnings per equity share (face value Re. 1 per share) (a) Basic (in Rs.)						(annualise 40.
(g) dask (iii hs.)	10.92	10.85	10.44	21.77	18.21	40.





#### NOTES:

- 1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above conoslidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 November 2019. The statutory auditors have carried out limited review of the above results for the guarter and Half year ended 30 September 2019. An ungualified report has been issued by them thereon.
- 4 Effective 1 April 2019, the Group adopted Ind-AS 116, on all lease contracts existing on 1 April 2019 using the modified retrospective method with Right-of-use assets recognized at an amount equal to the lease liabilities in the balance sheet. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. On transition, the adoption of the standard resulted in recognition of Right-of-use assets (ROU) of Rs. 51,977 lakhs (includes reclassification of finance lease assets of Rs. 11,594 lakhs as at 31 March 2019) and lease liabilities of Rs. 47,535 lakhs (includes reclassification of finance lease obligations of Rs. 7,152 lakhs as at 31 March 2019). The Right-of-use assets as on 30 September 2019 have been presented as part of Property, plant and equipment.
- 5 Exceptional items for the current period/year represent acquisition related costs.
- 6 The Group operates in only one segment viz., 'Pharmaceutical Products'.
- 7 The Company has alloted 23,000 equity shares of Re.1/- (Rupee One only) on 7 August, 2019 to the employees under Employee Stock option plan 2006. Consequent to the allotment, the paid-up share capital of Company has increased from 58,59,15,609 to 58,59,38,609 equity shares of Re.1/- each. These were fully vested during the year ended 31 March 2017.
- 8 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendement) Ordinance 2019, inserted a new Section 115BAB in the Income tax Act, 1961, which provides an option to the companies for paying income Tax at reduced rates as per the provisions/conditions defined in the said section. The Group is in the process of evaluting its position with respect to the aforesaid option.
- 9 The Board in its meeting held on 28 May 2019 approved the Scheme of Arnalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited with the Parent Company. The Parent Company has filed an Application C.A. (CAA) NO. 201/230/HDB/2019 before the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT) on 7 August 2019. The NCLT had passed an Order on 30 September 2019 and directed to convene the meetings of Equity Shareholders and Un-secured Creditors of the Parent company and the subsidiaries covered under merger scheme, on 30 November 2019.
- 10 SEBI (Securities and Exchange Board of India) vide notification dated 9 May 2018 mandated submission of the statement of cash flows by way of a note as part of the half yearly financial results w.e.f 1 April 2019. Since this is the first period/year of requirement for submission of the statement of cash flows and as there is no specific gudiance by SEBI, the comparative information has been provided for the previous year ending 31 March 2019.

By Order of the Board

11 The Board has approved interim dividend @125% i.e.Re.1.25 (Rupee One and Twenty five paise only) per equity share of Re.1 (Rupee One only) for the year 2019-20.

12 Previous period figures have been regrouped/ rearranged wherever considered material and necessary to conform to the current period presentation.

PH. N. Govindarajan 20 Place: Hyderabad 0 Managing Director www.auroffu Date :12 November 2019 DIN-00050482 HYD ASSOCIO

FOR IDENTIFICATION ONLY

ED ACCO

SI. P			and the second se
	PARTICULARS	As at	As at
10.		30.09.2019 (Unaudited)	31.03.2019 (Audited)
+		(Unaudited)	(Audited)
A	SSETS		
1 N	on-current assets	1.2.5.2	
P	roperty, plant and equipment	626,702	569,36
C	apital work-in-progress	152,451	134,19
G	oodwill	83,150	83,25
0	ther intangible assets	184,203	194,86
In	tangible assets under development	34,704	32,65
lin	vestments accounted for using the equity method	34,782	24,75
	nancial assets		
1	Investments	12,043	11,26
	Loans	535	64
	Trade receivables	85	11
- 10	Other financial assets	12,340	8,93
0	eferred tax assets (net)	16,914	18,32
	on- current tax assets (net)	17,391	13,81
	ther non-current assets	23,506	16,79
		1,198,806	1,108,98
T	otal non-current assets	1,198,800	1,108,98
2 0	urrent assets		
C	ventories	759,274	724,56
F	nancial assets		
1	Investments	2	
1	Trade receivables	416,004	341,37
11	Cash and cash equivalents	206,134	188,37
11	Bank balances other than cash and cash equivalents	7,280	7,34
. 1	[3] A. M. M. Martin and A. M. M. Martin, "A static free days of the state of the	1,139	1,02
	Loans Other formed a sector	5,751	136,34
	Other financial assets		
1.1	urrent tax assets (net)	1,602	3,45
	ther current assets	132,944	133,96 1,536,45
Tree in the second seco	otal current assets	1,530,130	1,530,45
T(	DTAL ASSETS	2,728,936	2,645,43
E	QUITY AND LIABILITIES		
1 E	quity	and the second sec	
	quity share capital	5,859	5,85
	ther equity	1,513,460	1.383,21
	guity attributable to owners of the Parent Company	1,519,319	1,389,07
	on-controlling interest	111	15
	otal equity	1,519,430	1,389,23
	abilities	1.	
	on-current liabilities		
	nancial liabilities		
1.	Borrowings	2,416	17,99
1.	Lease liabilities	30,575	21,55
		5,708	4,65
	rovisions	34,264	28,13
	eferred tax liabilities (net)	4,351	1,13
	ther non-current liabilities otal non-current liabilities	77,314	51,91
	urrent liabilities		
F	nancial liabilities	FC3 036	657 22
1	Borrowings	562,826	657,32
1.	Lease liabilities	11,865	
	Trade payables	and the second	
	total outstanding dues of micro enterprises and small enterprises and	5,680	3,36
	total outstanding dues of creditors other than micro enterprises and small enterprises	255,894	264,35
1	Other financial liabilities	186,304	166,14
0	ther current liabilities	73,703	88,39
In.	rovisions	27,264	18,08
P			C (C)
	urrent tax liabilities (net)	8,656	6,62
C	urrent tax liabilities (net) otal current liabilities	8,656 1,132,192	1,204,29



FOR IDENTIFICATION ONLY



-	olidated statement of cash flows	1.0.0.01	(Rs. In lakhs
£	and the second se	For the half	For the year
<b>b</b> .	PARTICULARS	year ended	ended
1		30.09.2019	31.03.2019
-		(Unaudited)	(Audited)
1	CASH FLOW FROM OPERATING ACTIVITIES	1	
	Net profit before tax	172,734	309,135
1	Adjustments to reconcile profit before tax to net cash flows:		
ł	Depreciation and amortisation expense	48,417	66,79
1	Allowance for doubtful receivables/(written back) (net)	519	66
1	Liabilities no longer required written back (net)	(837)	(2,22
	Bad debts/advances written off	250	18
	Product destruction expenses / stock written off	528	30
	Mark-to-market gain on derivative financial instruments	(601)	(64
	Unrealised foreign exchange gain (net)	(737)	(65
	Loss on sale / write-off of property, plant and equipment (net)	773	1,94
	Share of profit of joint ventures	(478) 8,345	(27 15,07
	Finance costs	(1,032)	(1,37
	Interest income Effect of exchange rate changes	(1,250)	1,58
	Operating profit before working capital changes	226,631	390,52
	Movements in working capital:	100.000	100.00
	Increase in inventories	(35,241)	(88,60
	Increase in trade receivables	(68,283)	(1,76
	Decrease/(increase) in other financial assets	130,614	(56,27
	Increase in other current/non-current assets	(2,249)	(16,64
	Increase in loans Increase / (decrease) in trade payables	(2) 26,484	(26
	Increase / (decrease) in trade payables	9,489	(3,41
	(Decrease)/ increase in other current/non-current liabilities	(11,471)	30,39
	(Decrease) / increase in other financial liabilities	(12,143)	25,55
	Cash generated from operating activities	263,829	242,08
	Direct taxes paid (net of refunds)	(37,104)	(76,98
	Net cash generated from operating activities (A)	226,725	165,09
	CASH DI ONE FOOM INVESTING ACTIVITIES	1	
2	CASH FLOW FROM INVESTING ACTIVITIES	174 7601	11 40 55
	Purchase of property, plant and equipment, including movement in capital work- in- progress, capital	(74,260)	(142,56
	advances and capital creditors	14 504	142.24
	Purchase of intangible assets and intangible assets under development	(1,594)	(13,34
	Proceeds from sale of property, plant and equipment and intangible assets Acquisition of business	790	2,22 (121,16
1	Acquisition of subsidiaries, net of cash and cash equivalents acquired	2	(10,82
	Purchase of non-current investments	(9,997)	(4,63
	Bank balances not considered as cash and cash equivalents (net)	(2,674)	(2,57
1	Interest received	1.017	1,25
	Dividend received from joint venture	244	1,37
	Net cash used in investing activities (B)	(86,474)	(290,25
1		1	
3	CASH FLOW FROM FINANCING ACTIVITIES		
1	Proceeds from issuance of equity share capital	19	
	Repayment of non-current borrowings	(10,789)	(39,38
	(Repayment of)/proceeds from current borrowings (net)	(96,418)	262,42
	Finance costs paid	(7,528)	(15,15
1	Repayment of lease liabilities (net)	(7,128)	
	Dividends paid on equity shares	1 A 1	(14,60
	Tax paid on equity dividend Net cash (used in)/generated from financing activities (C)	(121,844)	(1,38
1	Her cear (used m)/ Benerates nom manning activities (c)	(accepted)	252,50
1	Net increase in cash and cash equivalents (A + B + C)	18,407	66,74
	Cash and cash equivalents at the beginning of the year	187,558	120,99
	Effect of exchange differences on cash and cash equivalents	158	(18
	Cash and cash equivalents at the end of the year	206,123	187,55
	Cash and cash empirishants comprise of		
	Cash and cash equivalents comprise of: Cash on hand	42	3
		42	2,82
	Cheques on hand Balance with banks		4,82
	- on current account	173,864	159,13
	- on current account - on cash credit account (net)	16,470	(34
	- on deposit account	15,747	25,90
J	Cash and Cash equivalents considered for cash flows	206,123	187,55

The above statement of cash flows has been prepared under the "Indirect method" as set out in Ind AS 7, "Statement of cash flows".





# **BSR&Associates LLP**

#### Chartered Accountants

Salarpuria Knowledge City Orwell, B Wing, 6th Floor, Unit-3 Sy. No. 83/1, Plot No. 2, Raidurg Hyderabad-500081, India. Telephone +91 40 7182 2000 Fax +91 40 7182 2399

Independent Auditor's Review Report on Unaudited Quarterly and Year to date Consolidated Financial Results of Aurobindo Pharma Limited under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

To

Board of Directors of Aurobindo Pharma Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Aurobindo Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its joint ventures for the quarter ended 30 September 2019 and year to date results for the period from 1 April 2019 to 30 September 2019 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Listing Regulations.
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

S.No.	Name of the component	Country	Relationship
1	APL Research Centre Limited	India	Subsidiary
2	APL Healthcare Limited	India	Subsidiary
3	Auronext Pharma Private Limited	India	Subsidiary
4	Silicon Life Sciences Private Limited	India	Subsidiary
5	Auro Peptides Limited	India	Subsidiary
6	APL Pharma Thai Limited	Thailand	Subsidiary
7	All Pharma (Shanghai) Trading Company Limited	China	Subsidiary
8	Aurobindo Pharma USA Inc.	USA	Subsidiary

4. The Statement includes the results of the following entities:

B S R & Associates (a partnership firm with Registration No BA99226) converted into B S R & Associates LLP (a Limited Liability Partnership with LLP Registration No AAB-B182) with effect from October 14, 2013 Registered Office: 5th Floor, Lodha Excelus Apolo Mills Compound N.M. Joshi Marg, Mehalakshmi Mumbei - 400 011

### B S R & Associates LLP Aurobindo Pharma Limited Limited review report (continued)

S.No.	Name of the component	Country	Relationshi
9	Natrol LLC	USA	Subsidiary
10	Aurolife Pharma LLC	USA	Subsidiary
11	Auro Health LLC	USA	Subsidiary
12	Auromedics Pharma LLC	USA	Subsidiary
13	Aurobindo Pharma USA LLC	USA	Subsidiary
14	Auro AR LLC	USA	Subsidiary
15	Auro Vaccines LLC	USA	Subsidiary
16	Auro Logistics LLC	USA	Subsidiary
17	Auro Packaging LLC	USA	Subsidiary
18	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Subsidiary
19	Helix Healthcare B.V.	The Netherlands	Subsidiary
20	Aurogen South Africa (Pty) Ltd	South Africa	Subsidiary
21	Aurobindo Pharma (Pty) Limited	South Africa	Subsidiary
22	Novagen Pharma (Pty) Limited	South Africa	Joint ventur
23	Auro Pharma Inc.	Canada	Subsidiary
24	Aurovida Farmaceutica SA DE CV	Mexico	Subsidiary
25	Aurobindo Pharma Japan K.K.	Japan	Subsidiary
26	Aurobindo Pharma Colombia S.A.S	Colombia	Subsidiary
27	Agile Pharma B.V.	The Netherlands	Subsidiary
28	Arrow Generiques SAS	France	Subsidiary
29	1980 Puren Pharma GmbH (formerly Actavis Management GmbH)	Germany	Subsidiary
30	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Germany	Subsidiary
31	Aurovitas Spain SA (formerly Actavis Spain S.A)	Spain	Subsidiary
32	Aurobindo Pharma B.V. (formerly Actavis B.V.)	The Netherlands	Subsidiary
33	Aurex B.V. (formerly Pharmacin B.V.)	The Netherlands	Subsidiary
34	Aurobindo Pharma GmbH	Germany	Subsidiary
35	Laboratorios Aurobindo S.L.	Spain	Subsidiary
36	Aurobindo Pharma (Italia) S.r.l	Italy	Subsidiary
37	Aurobindo Pharma (Romania) S.r.l.	Romania	Subsidiary
38	Pharmacin B.V. (formerly Aurex B.V.)	The Netherlands	Subsidiary
39	Aurobindo Pharma (Malta) Limited	Malta	Subsidiary
40	APL Swift Services (Malta) Limited	Malta	Subsidiary
41	Milpharm Limited	United Kingdom	Subsidiary
42	Aurovitas Pharma Polska	Poland	Subsidiary
43	Generis Farmaceutica S.A	Portugal	Subsidiary
44	Generis Phar, Unipessoal Lda.	Portugal	Subsidiary
45	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Subsidiary
46	Aurobindo Pharma Industria Farmaceutica Ltda	Brazil	Subsidiary
47	Hyacinths Pharma Private Limited	India	Subsidiary
48	Raidurgam Developers Limited (formerly Aurobindo Antibiotics Ltd)	India	Joint Venture
49	AuroZymes Limited	India	Subsidiary

#### B S R & Associates LLP Aurobindo Pharma Limited Limited review report (continued)

S.No.	Name of the component	Country	Relationship
50	Curepro Parenterals Limited	India	Subsidiary
51	Eugia Pharma Specialities Limited	India	Joint venture
52	Tergene Biotech Private Limited	India	Joint venture
53	Auro Pharma India Private Limited	India	Subsidiary
54	Aurovitas Pharma Ceska republika s.r.o	Czech Republic	Subsidiary
55	Aurovitas Pharma (Taizhou) Ltd	China	Subsidiary
56	Acrotech Biopharma LLC	USA	Subsidiary
57	Purple Bellflower (Pty) Ltd	South Africa	Joint Venture
58	Auroscience (Pty) Ltd	Australia	Subsidiary
59	Auro Science LLC	USA	Subsidiary
60	Apotex Nederland BV, NL	The Netherlands	Subsidiary
61	APOTEX ESPANA SL	Spain	Subsidiary
62	Aurovitas spol s.r.o (Formerly known as APOTEX CR spol.s.r.o)	Czech Republic	Subsidiary
63	Apotex SA/NV	Belgium	Subsidiary
64	Apotex Polska Sp.z.o.o	Poland	Subsidiary
65	Apotex Europe BV	The Netherlands	Subsidiary
66	Sameko Farma B.V.	The Netherlands	Subsidiary
67	Leidapharm B.V.	The Netherlands	Subsidiary
68	Marel B.V.	The Netherlands	Subsidiary
69	Pharma Dossier B.V.	The Netherlands	Subsidiary
70	Aurobindo Pharma FZ LLC, Dubai	U.A.E.	Subsidiary
71	Curateq Biologics GmbH	Switzerland	Subsidiary
72	Luoxin Aurovitas Pharm (Chengdu) Co., Ltd.	China	Joint Venture

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the interim financial information of 20 subsidiaries included in the Statement, whose interim financial information reflect total assets of Rs. 1,075,402 lakhs as at 30 September 2019 and total revenues (including other income) of Rs. 350,239 lakhs and Rs. 692,260 lakhs, total net profit after tax of Rs. 26,112 lakhs and Rs. 51,161 lakhs and total comprehensive income of Rs. 25,969 lakhs and Rs. 50,910 lakhs for the quarter ended 30 September 2019 and for the period from 1 April 2019 to 30 September 2019, respectively, and cash flows (net) of Rs. 689 lakhs for the period from 1 April 2019 to

#### B S R & Associates LLP Aurobindo Pharma Limited Limited review report (continued)

30 September 2019, as considered in the consolidated unaudited financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the financial results and other financial information of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments, if any made by the Parent's Management. Our conclusion in so far on the Statement as it relates to the balances and affairs of such subsidiaries located outside India is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

7. The Statement includes the interim financial information of 46 subsidiaries which have not been reviewed, whose interim financial information reflect total assets of Rs. 973,861 lakhs as at 30 September 2019 and total revenue (including other income) of Rs. 102,476 lakhs and Rs. 210,931 lakhs, total net profit after tax of Rs. 3,386 lakhs and Rs. 10,816 lakhs and total comprehensive income of Rs. 3,386 lakhs and Rs. 10,816 lakhs for the quarter ended 30 September 2019 and for the period from 1 April 2019 to 30 September 2019, respectively, and cash outflows (net) of Rs. 15,628 lakhs for the period from 1 April 2019 to 30 September 2019, as considered in the Statement. The Statement also includes the Group's share of net (loss)/ profit after tax of Rs. (26) lakhs and Rs. 229 lakhs for the quarter ended 30 September 2019 and for the period 30 September 2019 and for the period from 1 April 2019 and for the period from 1 April 2019 to 30 September 2019, respectively, as considered in the Statement. The Statement also includes the Group's share of net (loss)/ profit after tax of Rs. (26) lakhs and Rs. 229 lakhs for the quarter ended 30 September 2019 and for the period from 1 April 2019 to 30 September 2019, respectively, as considered in the consolidated unaudited financial results, in respect of 6 joint ventures, based on their interim financial information which have not been reviewed. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Associates LLP** Chartered Accountants Firm Registration Number: 116231W/W-100024

Sriram Mahalingam Partner Membership Number: 049642 UDIN: 1904-9642AAAEB8120

Place: Hyderabad Date: 12 November 2019



NEWS RELEASE

12<sup>th</sup> November 2019, Hyderabad, India

### Aurobindo Pharma Ltd Q2 FY19-20 Financial Results

### Consolidated Financial Results – Q2FY19-20

Amount in INR Cr	Q2	Q2	% Chg	Q1	% Chg
	FY19-20	FY18-19	70 Ong	FY19-20	vo eng
Revenue from Operations	5,600.5	4,751.4	17.9	5,444.6	2.9
EBITDA before Forex and Other income	1,167.5	1,026.0	13.8	1,146.4	1.8
EBITDA %	20.8%	21.6%		21.1%	
PBT before Forex and Exceptional Items	903.8	853.2	5.9	866.7	4.3
Net Profit after JV share, minority interest	639.5	611.4	4.6	635.7	0.6

### Key Highlights of Q2FY20 consolidated financials

- Revenue from Operations at INR 5,600.5 Cr, witnessed a strong growth of 17.9% over corresponding previous period
  - US formulations revenue of INR 2,835.5 Cr vs INR 2,226.8 Cr in Q2FY19, registering a robust growth of 27.3% YoY
  - Europe formulations revenue at INR 1,401.3 Cr, an increase of 21.2% against Q2FY19 last year
  - Growth Markets posted a growth of 3.8% YoY to INR 319.2 Cr
  - ARV formulations revenue at INR 237.9 Cr vs. INR 244.0 Cr, declined by 2.5% YoY
  - API revenue came in at INR 805.8 Cr vs. INR 816.6 Cr in the corresponding previous period
- EBIDTA before Forex and Other income at INR 1,167.5 Cr, grew by 13.8% year-on-year; EBITDA margin for the quarter was at 20.8%
- Net Profit after JV share, minority interest at INR 639.5 Cr as against INR 611.4 Cr in the corresponding previous period, witnessing a growth of 4.6% YoY
- Basic & Diluted EPS is INR 10.92 per share.
- Research & Development (R&D) spend at INR 222.9 Cr, 4.0% of revenues
- Received final approval for 3 ANDAs and tentative approval for 1 ANDA from USFDA
- Interim Dividend @ 125% i.e., INR 1.25 per equity share of INR 1/- has been approved by the Board for FY19-20

**Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said:** "We had an another quarter of healthy performance where we continued to grow in US and Europe, which are our focused geographies. Our R&D initiatives have been progressing well across the products basket and we have started clinical trials for our first biosimilar product in

### AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel: +91 40 6672 5000 / 1200 Fax: +91 40 6707 4059 Regd. Off.: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 Fax: +91 40 2374 7340, Email: info@aurobindo.com




Q3FY20. We reiterate that we are committed to quality adherence and are in the process of resolving all pending regulatory issues."


#### **Operational Performance (Consolidated):**

Amount in INR Cr	Q2 FY19-20	Q2 FY18-19	% Chg	Q1 FY19-20	% Chg
Formulations					
USA	2,835.5	2,226.8	27.3	2,688.4	5.5
Europe	1,401.3	1,156.5	21.2	1,391.6	0.7
Growth Markets	319.2	307.5	3.8	313.4	1.8
ARV	237.9	244.0	-2.5	318.5	-25.3
Total Formulations	4,793.8	3,934.8	21.8	4,712.0	1.7
Active Pharmaceuticals Ingredients (API)					
Betalactum	517.5	513.4	0.8	431.0	20.1
Non Betalactum	288.3	303.2	-4.9	301.2	-4.3
Total API	805.8	816.6	-1.3	732.2	10.1
Consolidated Sales	5,599.7	4,751.4	17.9	5,444.2	2.9
Dossier Income	0.8	0.0		0.4	
Revenue from Operations	5,600.5	4,751.4	17.9	5,444.6	2.9

Consolidated Revenue breakup - Geography & segment wise

#### <u>Q2FY20</u>





#### **Formulations**

Formulation revenue for the quarter posted a growth of 21.8% YoY to INR 4,793.8 Cr and accounted for 85.6% of total revenues.

#### **US Formulations**

• US revenue for Q2FY20 witnessed a growth of 27.3% YoY to INR 2,835.5 Cr, accounting 50.6% of consolidated revenue. On constant currency basis, revenue grew by 26.8% YoY

### AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

#### PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : + 91 40 6672 5000 / 1200 Fax : + 91 40 6707 4059 Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : + 91 40 2373 6370 Fax : + 91 40 2374 7340, Email : info@aurobindo.com

#### www.aurobindo.com



- Filed 20 ANDAs with USFDA including 2 injectables in Q2FY20
- Received final approval for 3 ANDAs and tentative approval for 1 ANDA
- The company has launched 10 products including 3 injectables during the quarter
- As on 30<sup>th</sup> Sept 2019, on a cumulative basis, the company filed 569 ANDAs with USFDA and received approval for 416 ANDAs including 27 tentative\* approvals *\*Tentative approvals include 9 ANDAs approved under PEPFAR.*

#### **EU Formulations**

• EU formulations revenue in Q2FY20 witnessed a growth of 21.2% YoY to INR 1,401.3 Cr, accounting 25.0% of consolidated revenue. In Euro terms, revenue grew by 26.1% YoY

#### **ARV Formulations**

• ARV business revenue for Q2FY20 was at INR 237.9 Cr Vs. INR 244.0 Cr in Q2FY19, down by 2.5% and accounted for 4.2% of revenue

#### Growth Markets Formulations

 Revenue from Growth markets formulations in Q2FY20 up by 3.8% YoY to INR 319.2 Cr and accounted for 5.7% of revenue

#### API business

- API business clocked a sales of INR 805.8 Cr Vs. INR 816.6 Cr in the corresponding previous period
- The company filed 3 DMFs with USFDA during the quarter.

#### **Global Regulatory Filings:**

Filings	Q2 FY19-20	Cumulative Filings as on 30 <sup>th</sup> Sep 2019
ANDAs (including filings made from Aurobindo USA)	20	569
DMFs (including filings made from AuroNext and AuroPeptide)	3	253
Formulations Dossiers in other key advanced markets (incl. Multiple registrations into Europe. South Africa and Canada)	62	3,732
API DMF/COS filings in other key regulated markets (incl. Multiple registrations)	51	3,004

### AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059 Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com



#### USFDA approvals received in Q2 FY19-20:

#### **Final Approvals**

1	Latanoprost (gXalatan) Ophthalmic Solution 0.005%	Ophthalmic
2	Pilocarpine Hydrochloride (gSalagen) Tablets 5 mg & 7.5 mg	Cholinergic Agent
3	Fenofibric Acid (gTrilipix) Delayed Release Capsules 45 mg and 135 mg	CVS

#### **Tentative Approvals**

1 Enzalutamide (gXtandi) Capsules 40 mg	Antineoplastic
---	----------------

#### Earnings call details

The company will host an earnings call at 8.30 AM IST on November 13<sup>th</sup> 2019, to discuss the performance and answer any questions from participants.

Participants can dial-in on the numbers below Primary Number: +91 22 6280 1437 / +91 22 7115 8825 Local Access Number: +91 70456 71221 (Available all over India)

#### About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN) headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The Company is marketing these products globally in over 150 countries.

#### For further information, please contact:

Krishna Kiran Investor Relations Phone:040-66725401 / 66725000 Mobile:+91 98486 67906 Email:ir@aurobindo.com

#### **Disclaimer:**

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information

### AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel: +91 40 6672 5000 / 1200 Fax: +91 40 6707 4059 Regd. Off.: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 Fax: +91 40 2374 7340, Email: info@aurobindo.com





AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax STATEMENT OF UNAUDITED CONSOLIDATED FIN					(Rs. In lakhs	s)	
STATEMENT OF UNAUDITED CONSOLIDATED FIN		Duarter ended	IER AND HALF	Half yea		Year ended	
Particulars	30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Revenue from operations							
(a) Net sales/ income from operations	5,51,827	5,35,684	4,66,712	10,87,511	8,84,868	19,22,592	
(b) Other operating income	8,220	8,776	8,428	16,996	15,299	33,763	
Total revenue from operations	5,60,047	5,44,460	4,75,140	11,04,507	9,00,167	19,56,35	
2 Other income							
(a) Foreign exchange gain (net)	-	478	-	-		-	
(b) Others	2,062	1,100	2,626	3,162	6,999	11,56	
Total other income Total income (1+2)	2,062 5,62,109	1,578 5,46,038	2,626 4,77,766	3,162 11,07,669		11,56 19,67,92	
	3,02,103	5,40,050	4,77,700	11,07,005	5,07,100	13,07,32	
3 Expenses							
(a) Cost of materials consumed	1,81,547	1,86,038	1,87,436	3,67,585		7,44,49	
(b) Purchase of stock-in-trade	51,570	53,007	44,402	1,04,577	87,915	1,94,32	
(c) Changes in inventories of finished goods, stock-in-trade and	3,715	(9,191)	(27,549)	(5,476)	(46,015)	(67,555	
work-in-progress							
(d) Employee benefits expense	77,719	77,986	62,548	1,55,705	1,22,161	2,58,48	
(e) Finance costs	4,094	4,989	3,539	9,083	6,493	16,26	
(f) Foreign exchange loss (net)	2,723	-	3,973	2,245	10,789	6,02	
(g) Depreciation and amortisation expense	24,331	24,086	16,368	48,417	31,821	66,79	
(h) Other expenses	1,28,751	1,21,980	1,05,703	2,50,731	2,02,470		
Total expenses	4,74,450	4,58,895	3,96,420	9,32,867	7,68,748	16,50,25	
4 Profit before share of profit of joint ventures, exceptional items	87,659	87,143	81,346	1,74,802	1,38,418	3,17,67	
and tax (1+2-3)							
5 Share of profit of joint ventures, net of tax	7	471	24	478	65	27	
6 Profit before exceptional items and tax (4+5)	87,666	87,614	81,370	1,75,280	1,38,483	3,17,94	
7 Exceptional items (refer note 5)	1,276	1,270	2,684	2,546	2,684	8,80	
8 Profit before tax (6-7)	86,390	86,344	78,686	1,72,734	1,35,799	3,09,13	
9 Tax expense							
Current tax	21,695	20,669	19,897	41,220	30,845	71,20	
Tax credit - Miminum Alternate Tax (MAT)	(237)	(1,144)	(3,539)	(237)	(4,207)	(5,100	
Deferred tax	979	3,251	1,184	4,230	2,458	6,57	
Total tax expense	22,437	22,776	17,542	45,213	29,096	72,68	
10 Profit for the period/year (8-9)	63,953	63,568	61,144	1,27,521	1,06,703	2,36,45	
<ul> <li>11 Other Comprehensive Income         <ul> <li>A) Items that will not be reclassified subsequently to profit or             loss:</li> </ul> </li> </ul>							
i) Re-measurement of defined employee benefit liability	(686)	(55)	8	(741)	(89)	(261	
ii) Income-tax relating to items that will not be reclasified to	239	19	1	258	35	107	
profit or loss			_				
<ul><li>B) Items that will be reclassified subsequently to profit or loss:</li><li>i) Exchange differences on translating the financial statements of</li></ul>	2,154	1,044	19,154	3,198	22,680	(266	
foreign operations	2,201	2,011	10,101	0,250	22,000	(=00	
ii) Income-tax on items that will be reclassified subsequently to	-	-	-	-	-	-	
profit or loss							
Total other comprehensive income for the period/year (net of tax)	1,707	1,008	19,163	2,715	22,626	(420	
12 Total Comprehensive income for the period/year (net of tax)		64,576	80,307	1,30,236	1,29,329	2,36,03	
Attributable to:	05,000	04,570	00,507	1,50,250	1,25,325	2,30,03	
Owners of the Parent Company	65,693	64,591	80,306	1,30,284	1,29,335	2,36,05	
Non-controlling interest	(33)	(15)	1	1,50,284 (48)	1,25,335	2,30,03	
Out of total comprehensive income above,	(33)	(15)	-	(-0)	(0)	(23	
Profit for the year attributable to:							
Owners of the Parent Company	63,986	63,583	61,151	1,27,569	1,06,709	2,36,47	
Non-controlling interest	(33)	(15)		1,27,569 (48)	1,00,709	2,50,47	
Other comprehensive income attributable to:	(33)	(13)	(7)	(40)	(0)	(23	
	1 707	1 000	19,163	3 715	22 626	1000	
Owners of the Parent Company Non-controlling interest	1,707	1,008	19,103	2,715	22,626	(420	
	-	-	-	-	-	-	
13 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859	5,85	
14 Other equity						13,83,21	
15 Earnings per equity share (face value Re. 1 per share)	(not annualised)					-	
(a) Basic (in Rs.)	10.92	10.85	10.44	21.77	18.21	40.3	
(b) Diluted (in Rs.)	10.92	10.85	10.44	21.77	18.21	40.3	

## **AUROBINDO PHARMA LIMITED**

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059 Regd. Off.: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: + 91 40 2373 6370 Fax: + 91 40 2374 7340, Email: info@aurobindo.com



#### NOTES:

- 1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above conoslidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 12 November 2019. The statutory auditors have carried out limited review of the above results for the quarter and Half year ended 30 September 2019. An unqualified report has been issued by them thereon.
- 4 Effective 1 April 2019, the Group adopted Ind-AS 116, on all lease contracts existing on 1 April 2019 using the modified retrospective method with Right-of-use assets recognized at an amount equal to the lease liabilities in the balance sheet. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. On transition, the adoption of the standard resulted in recognition of Right-of-use assets (ROU) of Rs. 51,977 lakhs (includes reclassification of finance lease assets of Rs. 11,594 lakhs as at 31 March 2019) and lease liabilities of Rs. 47,535 lakhs (includes reclassification of finance lease obligations of Rs. 7,152 lakhs as at 31 March 2019). The Right-of-use assets as on 30 September 2019 have been presented as part of Property, plant and
- 5 Exceptional items for the current period/year represent acquisition related costs.
- 6 The Group operates in only one segment viz., 'Pharmaceutical Products'.
- 7 The Company has alloted 23,000 equity shares of Re.1/- (Rupee One only) on 7 August, 2019 to the employees under Employee Stock option plan 2006. Consequent to the allotment, the paid-up share capital of Company has increased from 58,59,15,609 to 58,59,38,609 equity shares of Re.1/- each. These were fully vested during the year ended 31 March 2017.
- 8 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendement) Ordinance 2019, inserted a new Section 115BAB in the Income tax Act, 1961, which provides an option to the companies for paying income Tax at reduced rates as per the provisions/conditions defined in the said section. The Group is in the process of evaluting its position with respect to the aforesaid option.
- 9 The Board in its meeting held on 28 May 2019 approved the Scheme of Amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited with the Parent Company. The Parent Company has filed an Application C.A. (CAA) NO. 201/230/HDB/2019 before the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT) on 7 August 2019. The NCLT had passed an Order on 30 September 2019 and directed to convene the meetings of Equity Shareholders and Un-secured Creditors of the Parent company and the subsidiaries covered under merger scheme, on 30 November 2019.
- 10 SEBI (Securities and Exchange Board of India) vide notification dated 9 May 2018 mandated submission of the statement of cash flows by way of a note as part of the half yearly financial results w.e.f 1 April 2019. Since this is the first period/year of requirement for submission of the statement of cash flows and as there is no specific gudiance by SEBI, the comparative information has been provided for the previous year ending 31 March 2019.
- 11 The Board has approved interim dividend @125% i.e.Re.1.25 (Rupee One and Twenty five paise only) per equity share of Re.1 (Rupee One only) for the year 2019-20.

12 Previous period figures have been regrouped/ rearranged wherever considered material and necessary to conform to the current period presentation.

By Order of the Board

		N. Govindarajan
Place: Hyderabad		Managing Director
Date :12 November 2019	www.aurobindo.com	DIN-00050482

### AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel: +91 40 6672 5000 / 1200 Fax: +91 40 6707 4059 Regd. Off.: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 Fax: +91 40 2374 7340, Email: info@aurobindo.com

www.aurobindo.com



i. o.	DADTICULADC		(Rs. In lakhs
o.	PARTICULARS	As at	As at
		30.09.2019	31.03.2019
+		(Unaudited)	(Audited)
	ASSETS		
	Non-current assets		
	Property, plant and equipment	6,26,702	5,69,36
	Capital work-in-progress	1,52,451	1,34,19
- 1	Goodwill	83,150	83,25
- 1	Other intangible assets	1,84,203	1,94,86
- 1	Intangible assets under development	34,704	32,65
	Investments accounted for using the equity method	34,782	24,75
	Financial assets	-,-	, -
	Investments	12,043	11,26
	Loans	535	64
	Trade receivables	85	11
	Other financial assets	12,340	8,93
	Deferred tax assets (net)	16,914	18,32
- 1	Non- current tax assets (net)	17,391	13,81
- 1	Other non-current assets	23,506	16,79
- 1	Total non-current assets	11,98,806	11,08,98
		,_,_,_	,,
2	Current assets		
	Inventories	7,59,274	7,24,56
	Financial assets		
	Investments	2	
	Trade receivables	4,16,004	3,41,37
	Cash and cash equivalents	2,06,134	1,88,37
	Bank balances other than cash and cash equivalents	7,280	7,34
	Loans	1,139	1,02
	Other financial assets	5,751	1,36,34
	Current tax assets (net)	1,602	3,45
	Other current assets	1,32,944	1,33,96
	Total current assets	15,30,130	15,36,45
	TOTAL ASSETS	27,28,936	26,45,43
	EQUITY AND LIABILITIES		
- 1	Equity		
- 1	Equity share capital	5,859	5,85
	Other equity	15,13,460	13,83,21
	Equity attributable to owners of the Parent Company		
- 1		15 10 310	13 89 07
		15,19,319	
	Non-controlling interest	111	15
			15
	Non-controlling interest Total equity	111	15
	Non-controlling interest Total equity Liabilities	111	15
2	Non-controlling interest Total equity Liabilities Non-current liabilities	111	15
<u>2</u>	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities	111 15,19,430	15 13,89,23
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings	111 15,19,430 2,416	15 13,89,23
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities	111 15,19,430 2,416 30,575	15 <b>13,89,23</b> 17,99
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions	111 15,19,430 2,416 30,575 5,708	15 <b>13,89,23</b> 17,99 - 4,65
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net)	111 15,19,430 2,416 30,575 5,708 34,264	15 <b>13,89,23</b> 17,99 - 4,65 28,13
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351	15 13,89,23 17,99 - 4,65 28,13 1,13
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net)	111 15,19,430 2,416 30,575 5,708 34,264	15 13,89,23 17,99 - 4,65 28,13 1,13
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351	15 13,89,23 17,99 - 4,65 28,13 1,13
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total non-current liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351	15 13,89,23 17,99 - 4,65 28,13 1,13
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total non-current liabilities Current liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351	15 <b>13,89,23</b> 17,99 - - 4,65 28,13 1,13 <b>51,91</b>
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total non-current liabilities Eurrent liabilities Financial liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314 5,62,826	15 <b>13,89,23</b> 17,99 - - 4,65 28,13 1,13 <b>51,91</b>
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total non-current liabilities Eurrent liabilities Financial liabilities Borrowings	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314	15 <b>13,89,23</b> 17,99 - - 4,65 28,13 1,13 <b>51,91</b>
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314 5,62,826	15 <b>13,89,23</b> 17,99 - 4,65 28,13 1,13 <b>51,91</b> 6,57,32
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities (net) Other non-current liabilities Total non-current liabilities Current liabilities Borrowings Lease liabilities Trade payables total outstanding dues of micro enterprises and small enterprises and	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314 5,62,826 11,865	<b>13,89,07</b> 15 <b>13,89,23</b> 17,99 - 4,65 28,13 1,13 <b>51,91</b> 6,57,32 - 3,36 2,64,35
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total non-current liabilities Financial liabilities Evernet liabilities Borrowings Lease liabilities Borrowings Lease liabilities Trade payables total outstanding dues of micro enterprises and small enterprises and small enterprises	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314 5,62,826 11,865 5,680 2,55,894	15 <b>13,89,23</b> 17,99 - 4,65 28,13 1,13 <b>51,91</b> 6,57,32 - 3,36 2,64,35
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables total outstanding dues of micro enterprises and small enterprises Other financial liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314 5,62,826 11,865 5,680 2,55,894 1,86,304	15 <b>13,89,23</b> 17,99 - 4,65 28,13 1,13 <b>51,91</b> 6,57,32 - 3,36 2,64,35 1,66,14
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities (net) Other non-current liabilities Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables total outstanding dues of micro enterprises and small enterprises and total outstanding dues of creditors other than micro enterprises and small enterprises Other financial liabilities Trade payables total outstanding dues of creditors other than micro enterprises and small enterprises Other financial liabilities Other current liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314 5,62,826 11,865 5,680 2,55,894 1,86,304 73,703	15 <b>13,89,23</b> 17,99 - 4,65 28,13 1,13 <b>51,91</b> 6,57,32 - 3,36 2,64,35 1,66,14 88,35
3	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities (net) Other non-current liabilities Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables total outstanding dues of micro enterprises and small enterprises and total outstanding dues of creditors other than micro enterprises and small enterprises Other current liabilities Other current liabilities Provisions	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314 5,62,826 11,865 5,680 2,55,894 1,86,304 73,703 27,264	15 <b>13,89,23</b> 17,99 - 4,65 28,13 1,13 <b>51,91</b> 6,57,32 - 3,36 2,64,35 1,66,14 88,39 18,08
3	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities (net) Other non-current liabilities Total non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables total outstanding dues of micro enterprises and small enterprises and total outstanding dues of creditors other than micro enterprises and small enterprises Other financial liabilities Trade payables total outstanding dues of creditors other than micro enterprises and small enterprises Other financial liabilities Other current liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314 5,62,826 11,865 5,680 2,55,894 1,86,304 73,703 27,264 8,656	15 <b>13,89,23</b> 17,99 - 4,65 28,13 1,13 <b>51,91</b> 6,57,32 - 3,36 2,64,35 1,66,14 88,35 1,66,14 88,35 18,08 6,62
2	Non-controlling interest Total equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Total non-current liabilities Current liabilities Financial liabilities Financial liabilities Financial liabilities Trade payables total outstanding dues of micro enterprises and small enterprises and total outstanding dues of micro enterprises and small enterprises and small enterprises Other financial liabilities Other current liabilities Other current liabilities Provisions Current tax liabilities	111 15,19,430 2,416 30,575 5,708 34,264 4,351 77,314 5,62,826 11,865 5,680 2,55,894 1,86,304 73,703 27,264	15 <b>13,89,23</b> 17,99 - 4,65 28,13 1,13 <b>51,91</b> 6,57,32 - 3,36 2,64,35 1,66,14 88,39 18,08

## AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : + 91 40 6672 5000 / 1200 Fax : + 91 40 6707 4059 Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : + 91 40 2373 6370 Fax : + 91 40 2374 7340, Email : info@aurobindo.com